Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanubrutinib - BeiGene

Next Previous
X
Search
Drug Profile

Zanubrutinib - BeiGene

Alternative Names: BGB-3111; BRUKINSA

Latest Information Update: 17 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Developer BeiGene; Medison Pharma
  • Class Amides; Antineoplastics; Phenyl ethers; Piperidines; Pyrazoles; Pyrimidines; Small molecules; Urologics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia; Mantle-cell lymphoma; Follicular lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Phase III B-cell lymphoma
  • Phase II/III Membranous glomerulonephritis
  • Phase II CNS cancer; Diffuse large B cell lymphoma; Lupus nephritis; Lymphoma; SARS-CoV-2 acute respiratory disease
  • Phase I/II Haematological malignancies; Solid tumours

Most Recent Events

  • 15 Oct 2024 BeiGene plans a phase II trial for Chronic lymphocytic leukaemia (Monotherapy, Combination therapy, First-line therapy) (PO) in December 2024 (NCT06637501)
  • 28 Aug 2024 BeiGene completes a phase-I/II clinical trials in Haematological malignancies and Solid tumors (Monotherapy, Combination therapy, Second-line therapy or greater, Late-stage disease) in Australia, China (PO) (NCT04282018)
  • 26 Aug 2024 BeiGene completes a phase II trial in Lupus nephritis in China (PO) (NCT04643470)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top